1. Articles in category: Side-Effects

    1-24 of 81 1 2 3 4 »
    1. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      Front Immunol. 2018;9:1355

      Authors: Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL

      Read Full Article
      Mentions: Antibody COG
    2. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model

      Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model

      Cancer Therapy: Preclinical Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model Ferro Nguyen , Ivan Alferiev , Peng Guan , David T. Guerrero , Venkatadri Kolla , Ganesh S. Moorthy , Michael Chorny and Garrett M. Brodeur Ferro Nguyen PDF Abstract Purpose: Currently, <50% of high-risk pediatric solid tumors like neuroblastoma can be cured, and many survivors experience serious or life-threatening toxicities, so more effective, less toxic therapy is needed. One approach is to target drugs to tumors using nanoparticles, which take advantage of the enhanced permeability of tumor vasculature. Experimental Design: SN38, the active metabolite of ...

      Read Full Article
      Mentions: Nanoparticles
    3. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Expert Opin Biol Ther. 2018 May 04;:

      Authors: Shum T, Kruse RL, Rooney CM

      Abstract INTRODUCTION: Cancer therapy has been transformed by the demonstration that tumor-specific T-cells can eliminate tumor cells in a clinical setting with minimal long-term toxicity.

      Read Full Article
    4. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Int J Clin Oncol. 2018 Apr 26;:

      Authors: Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A, Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

      Read Full Article
    5. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.

      Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.

      J Pediatr Hematol Oncol. 2018 Apr 10;:

      Authors: Ferry I, Kolesnikov-Gauthier H, Oudoux A, Cougnenc O, Schleiermacher G, Michon J, Bogart E, Chastagner P, Proust S, Valteau-Couanet D, Defachelles AS

      Read Full Article
    6. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

      Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

      Pediatr Blood Cancer. 2018 Mar 30;:e27023

      Authors: Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR

      Read Full Article
      Mentions: Refractory NANT
    7. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

      Vorinostat combined with retinoids produces additive antitumor effects in preclinical studies of neuroblastoma. Higher systemic exposures of vorinostat than achieved in pediatric phase I trials with continuous daily dosing are necessary for in vivo increased histone acetylation and cytotoxic activity.

      Read Full Article
      Mentions: Refractory NANT
    8. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.

      Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.

      Pharm Res. 2018 Mar 07;35(4):85

      Authors: Gholizadeh S, Dolman EM, Wieriks R, Sparidans RW, Hennink WE, Kok RJ

      Abstract PURPOSE: Sepantronium bromide (YM155) is a hydrophilic quaternary compound that cannot be administered orally due to its low oral bioavailability; it is furthermore rapidly eliminated via the kidneys.

      Read Full Article
    9. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

      Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

      Pediatr Blood Cancer. 2018 Jan 19;:

      Authors: Ceylan K, Jahns LJ, Lode BN, Ehlert K, Kietz S, Troschke-Meurer S, Siebert N, Lode HN

      Read Full Article
      Mentions: Antibody Treatment
    10. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma

      The monoclonal anti-GD2 antibody ch14.18/CHO in combination with IL-2 is active and effective in high-risk neuroblastoma (NB) patients. Here, we investigated the inflammatory response and treatment tolerance of long-term infusion (LTI) of ch14.18/CHO (10 × 10 mg/m2; 24 hr) in combination with subcutaneous (s.c.) IL-2 in a single center program.

      Read Full Article
      Mentions: Antibody Treatment
    11. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Pediatr Hematol Oncol. 2017 Nov 17;:1-12

      Authors: Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J

      Read Full Article
      Mentions: Treatment MYCN
    12. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      MAbs. 2017 Nov 09;:0

      Authors: Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN

      Read Full Article
    13. Emerging and investigational therapies for neuroblastoma.

      Emerging and investigational therapies for neuroblastoma.

      Expert Opin Orphan Drugs. 2017;5(4):355-368

      Authors: Applebaum MA, Desai AV, Glade Bender JL, Cohn SL

      Abstract INTRODUCTION: Treatment for children with clinically aggressive, high-risk neuroblastoma remains challenging. Less than 50% of patients with high-risk neuroblastoma will survive long-term with current therapies, and survivors are at risk for serious treatment-related late toxicities.

      Read Full Article
      Mentions: Treatment
    14. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma.

      A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma.

      Clin Cancer Res. 2017 Sep 22;:

      Authors: Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, Meagher M, Shafer A, Ng CY, Leung W, Janssen WE, Wu J, Mao S, Brennan RC, Santana VM, Pappo A, Furman WL

      Read Full Article
    15. Therapeutic plasma exchange for a case of refractory opsoclonus myoclonus ataxia syndrome

      Opsoclonus myoclonus ataxia syndrome (OMAS) can be refractory to standard therapies and devastating. Alternative treatments are imperative. A 14-month-old male diagnosed with neuroblastoma and paraneoplastic OMAS achieved complete cancer remission with chemotherapy. The OMAS, however, persisted over the subsequent 4 years despite numerous immune-modulatory and immunosuppressive therapies.

      Read Full Article
    16. Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies

      Background: The purpose of this study was to determine the feasibility and tolerability of tandem courses of high-dose thiotepa with autologous hematopoietic cell rescue (AHCR) in patients with recurrent, refractory solid tumors who were ineligible for a single course of high-dose therapy due to greater than minimal residual disease. Patients with decreased hearing or poor renal function were eligible.

      Read Full Article
      Mentions: Refractory
    17. Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After (131)I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma.

      Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After (131)I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma.

      Int J Radiat Oncol Biol Phys. 2017 Oct 01;99(2):468-475

      Authors: Campbell K, Karski EE, Olow A, Edmondson DA, Kohlgruber AC, Coleman M, Haas-Kogan DA, Matthay KK, DuBois SG

      Read Full Article
    18. Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

      Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Aug 14;:

      Authors: Glincher R, Price AP, LaQuaglia MP, Kushner BH, Modak S

      Abstract The antivascular endothelial growth factor antibody, bevacizumab, is effective against several malignancies in adults but unproven in pediatric oncology. In early phase pediatric studies toxicities were similar to those in adults.

      Read Full Article
      Mentions: Antibody
    19. A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

      Conditions :   Relapsed or Refractory Malignancies;   Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL);   Relapsed or Refractory Acute Myeloid Leukemia (AML);   Relapsed or Refractory Non-Hodgkin Lymphoma (NHL);   Relapsed or Refractory Neuroblastoma;   Relapsed or Refractory Tumors That Expresses B Cell Lymphoma 2 (BCL-2) Interventions :   Drug: venetoclax;   Drug: chemotherapy Sponsors :   AbbVie;   Genentech/Roche Not yet recruiting - verified July 2017

      Read Full Article
      Mentions: Refractory
    20. Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations

      Conditions :   Advanced Malignant Solid Neoplasm;   BRAF Gene Mutation;   GNA11 Gene Mutation;   GNAQ Gene Mutation;   Histiocytosis;   HRAS Gene Mutation;   KRAS Gene Mutation;   NF1 Gene Mutation;   NRAS Gene Mutation;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Stage III Childhood Non-Hodgkin Lymphoma;   Stage IV Childhood Non-Hodgkin Lymphoma Interventions :   Other: Laboratory Biomarker Analysis;   Drug: Selumetinib Sponsor :   National Cancer Institute (NCI) Not yet recruiting - verified July 2017

      Read Full Article
      Mentions: Refractory
    1-24 of 81 1 2 3 4 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (1 articles) COG
  4. Researches in the News

    1. (1 articles) Antibody
    2. (1 articles) DFMO